Stefan Sperl
Ophthalmology
PANOPTES PHARMA
Austria
Biography
Stefan Sperl is co-founder and COO of Panoptes Pharma. Prior to this position he was global Project Manager at Nabriva Therapeutics AG, responsible for all development programs ranging from early preclinical to clinical phase 2 programs. Before that he headed the project management at Biovertis AG and was responsible for the internal and external drug discovery programs with emphasis on structure-based hit-to-lead optimizations. From 2000 to 2005, Dr. Sperl headed the small molecule research unit at Wilex AG, where he was responsible for lead optimization and GMP production. He has invented several patents of small molecules currently in clinical development. Dr. Stefan Sperl received his PhD in Chemistry from the Max Planck Institute in Martinsried, Germany in 2000.
Research Interest
Opthalmology
